Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

INTRODUCTION. Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), may underestimate activity and does not predict survival in patients with hepatocellular carcinoma (HCC) treated with sorafenib. This study assessed the value of alternative radiological criteria to evaluate respon...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ronot, Maxime, Bouattour, Mohamed, Wassermann, Johanna, Bruno, Onorina, Dreyer, Chantal, Larroque, Béatrice, Castera, Laurent, Vilgrain, Valérie, Belghiti, Jacques, Raymond, Eric, Faivre, Sandrine
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2014
Assuntos:
Hepatobiliary
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3983809/
https://ncbi.nlm.nih.gov/pubmed/24652387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0114
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares